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Amantadine is widely used in treating inﬂuenza A, hepatitis, Parkinson’s disease, and fatigue in multiple
sclerosis. In the past, only a few case reports have demonstrated that amantadine is associated with
corneal edema, endothelial dysfunction, and other corneal comorbidity. We herein present four cases
with reversible corneal edema and endothelial loss after taking amantadine, including two cases with
delayed presentation of corneal edema after use of amantadine for 18 months and 12 months.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Amantadine was originally utilized as an antiviral medication
for inﬂuenza A or hepatitis.1 It was later introduced in the treat-
ment of Parkinson’s disease, associated drug-induced dyskinesia,
and even fatigue of multiple sclerosis patients.1,2 Corneal edema
associated with amantadine therapy has been noticed during the
past 4 decades, with few cases having been reported in the litera-
ture.3e11 Here, we report four cases of corneal edema and endo-
thelial cell loss caused by oral intake of amantadine.2. Case reports
2.1. Case 1
An 80-year-old female with a history of dementia and bipolar
disease consulted our clinic due to bilateral blurred vision. She had
undergone bilateral cataract surgery 6 months previously un-
eventfully. At the ﬁrst presentation in our clinic, her best-corrected
visual acuities (BCVAs) of the right and left eyes were 0.3 and 0.05,f interest to declare.
mology, Kaohsiung Medical
00, Tzyou 1st Road, Sanmin
. Hsu).
ciety of Taiwan. Published by Elserespectively. Slit-lamp examination revealed bilateral corneal
stromal edema (Fig. 1). The anterior chamber was silent, both the
intraocular lenses were in good positions, and the intraocular
pressure was normal. Optical coherence tomography (OCT) showed
the corneal thickness of the right and left eyes to be 650 mm and
731 mm, respectively. In the absence of infectious or inﬂammatory
signs, pseudophakic bullous keratopathy or virus infection-related
corneal edema was suspected. Topical 3% NaCl and Alphagan were
given for relieving corneal edema. Two weeks later, corneal edema
in both eyes decreased slightly, to 625 mm and 730 mm, respectively.
Her medication was then carefully reviewed, which was as fol-
lows: triazolam 0.25 mg/day, amantadine 200 mg/day, quetiapine
200 mg/day, and bupropion 150 mg/day. Among these drugs,
amantadine was prescribed 3 weeks prior to the initiation of ocular
symptoms. Considering the possible side effect of amantadine to
induce the corneal edema, we suggested discontinuation of
amantadine use. However, this suggestion was disapproved by her
psychiatrist due to the clinical demand for her psychological
symptoms. Two months later, the patient’s corneal edema and
Descemet’s membrane wrinkling deteriorated. To rule out virus
infection, polymerase chain reaction of aqueous humor was per-
formed for the detection of cytomegalovirus and herpes simplex
virus, and the results were negative for both viruses. After further
discussion with the psychiatrist, amantadine was eventually dis-
continued. The corneal edema subsided gradually. Four weeks after
the cessation of amantadine, BCVAs of both eyes improved to 0.6.
Corneal thickness of the right and left eyes decreased to 484 mmvier Taiwan LLC. All rights reserved.
Fig. 1. Bilateral corneal edema with a corneal thickness of 650 mm in the right eye and
731 mm in the left eye (Case 1).
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endothelium counts were 1828 cell/mm2 and 1927 cell/mm2,
respectively. Hexagonicity of endothelial cells decreased in the left
eye, with a large amount of cells having irregular shapes (Fig. 2).
The last follow-up was 3months after cessation of amantadine, and
the BCVA remained at 0.6 in both eyes.Fig. 2. Decreased endothelial cell count with increased polymorphism and poly-
megathism (Case 1).2.2. Case 2
A 53-year-old female with Parkinson’s disease and major
depression suffered from painless blurred vision, with visual
hallucination for 3 weeks. She had undergone bilateral cataract
surgery 2 years previously. When she visited our clinic, the BCVA
was 0.1 in both eyes. Slit-lamp examination showed bilateral
corneal stromal edema in the central one-third (Fig. 3). In the
absence of an anterior chamber reaction or vitreous opacity, 1%
prednisolone and 3% NaCl were prescribed for treating the corneal
edema. However, no subjective visual improvement was noticed
after 2 weeks of treatment.
We reviewed her medication and found that she was taking
levodopa, pramipexole, and amantadine for Parkinson’s disease
from 6 weeks prior to the onset of ocular symptoms; additionally,
she took quetiapine for depression. Without an obvious cause of
corneal edema, amantadine-related corneal edema was suspected.
Amantadine was thus discontinued with approval from her
neurologist. Twoweeks later, her BCVA of the right eye remained at
0.1, but that of the left eye improved to 0.4. OCT showed the corneal
thickness of the right and left eyes to be 739 mm and 697 mm,
respectively. One percent prednisolone was then tapered gradually.
Four weeks later, her BCVA improved to 0.7 in both eyes, and the
corneal thickness decreased to 560 mm and 565 mm, respectively.2.3. Case 3
A 72-year-old female with Parkinson’s disease complained of
gradual bilateral blurring of vision for 1 month. She denied ocular
trauma or surgery history. No other ocular symptoms such as
tearing, pain, and foreign body sensation were observed. On the
ﬁrst ophthalmologic visit, the BCVAs of the right and left eyes were
0.04 and 0.06, respectively. The autorefractor failed to show the
refraction data. During slit-lamp examination, bilateral symmetric
corneal edema in the central two-thirds and Descemet’s membrane
folding were found. No guttata was observed, and the anterior
chamber was quiet. Grade 2 cataracts were noted in both eyes.
There was no conjunctival congestion or chemosis. Fundus was
veiled due to corneal edema even after mydriasis, but there was
normal retinal red reﬂex and the optic discs were not pale.
Pachymetry and specular microscopic endothelial count failed due
to marked corneal edema. Intraocular pressure and light reﬂex
were normal. Sonography showed no vitreous opacity or retinal
detachment. After reviewing her medication history, it was found
Fig. 3. With marked corneal edema, the best corrected visual acuity of both eyes was
0.1 (Case 2).
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kinson’s disease. In addition, visual hallucination was noticed by
her family. Under the suspicion of amantadine-induced corneal
edema, amantadine was discontinued after discussion with her
neurologist. Topical 0.1% dexamethasone was prescribed.
The corneal edema resolved completely 4 weeks after cessation
of amantadine. The BCVAs of the right and left eyes improved to 0.5
and 0.7, respectively. Specular microscopy showed that endothelial
cell densities were only 1149/mm2 and 1256/mm2, respectively.
Final corneal thicknesses were measured as 566 mm and 552 mm,
respectively.
2.4. Case 4
A 66-year-oldmale consulted our clinic with the chief complaint
of ﬂoater for 1 month and blurred vision for 4 days accompanied
with visual hallucination. Slit-lamp examination revealed central
corneal edema with Descemet’s membrane folding. The anterior
chamber was silent without cell or keratic precipitate. The BCVA of
the right eye was 0.2 under a correction of þ8.0 D with a history of
amblyopia, and that of the left eye was 0.4. The patient was taking
various medications for depression and Parkinson’s disease, pre-
scribed by different hospitals. Corneal thicknesses of the right and
left eyes were 834 mm and 851 mm, respectively. Specular micro-
scopy failed due to swollen cornea. Although the patient did not
bring his drug list with him, amantadine-induced corneal kerat-
opathy was suspected on the basis of our previous experience.
Three percent NaCl and 0.1% ﬂuorometholone were prescribed for
symptomatic relief. The patient was instructed to check his medi-
cine at home and stop amantadine if there were any being taken;
later, the use of amantadine 200 mg/day for 12 months was
conﬁrmed and ceased with the approval of his neurologist. One
month later, the BCVAs were improved to 0.5 and 0.8, respectively,
for the right and left eyes. Corneal thicknesses decreased to 593 mm
and 595 mm, and endothelial densities were 1730/mm2 and 1704/
mm2, respectively.3. Discussion
Amantadine is an antiviral drug originally used as a prophylactic
and for the treatment of inﬂuenza A and hepatitis.1 People have
found it to be useful as an antiparkinsonian agent, although the
mechanism is not well understood.1 Besides, it has also been uti-
lized in treating fatigue of multiple sclerosis patients.2 For treating
viral diseases, amantadine is used for a short period only. For Par-
kinson’s disease or multiple sclerosis, it may be used for months to
years.
Some systemic side effects of amantadine have been noted,
including cardiac dysfunction, psychiatric illness, seizure, periph-
eral edema, dry mouth, and nasal irritation.1 Ocular side effects
include superﬁcial punctate keratitis,1,5e7 punctate subepithelial
opacities, epithelial edema,10 and stromal edema.8e11 The side-
effect occurrence rate of amantadine has been reported to be
around 5e20%.1 Nevertheless, symptoms are generally mild and
transient, and seen mainly with dosages higher than 200 mg/day.1
Ophthalmologic adverse events of amantadine have been reported
since the 1970s, which include transient and sudden visual dete-
rioration resulting from bilateral corneal edema after weeks of
amantadine therapy. The corneal edema usually resolved after
cessation of amantadine, but has been known to recur after the
drug was resumed.5e8
As reported in previous studies, corneal edema has occurred
weeks, months, and even years after amantadine therapy, with
most of them taking place within 2 years.5e8 In our ﬁrst two cases,
the onset of corneal edema was 3e4 weeks after taking amanta-
dine. However, it occurred 18 months and 12 months after the
institution of amantadine in our third and fourth cases, respec-
tively. Moreover, there are four reported cases in the literature
demonstrating the occurrence of corneal edema following a pro-
longed period (up to 3e8 years) after starting amantadine ther-
apy.4,9,11 The large variability in the corneal edema onset time
after administration of amantadine may be related to the different
endothelial cell densities at baseline in different patients. Besides,
despite the mechanism of amantadine-induced corneal edema
not being clear, idiosyncratic hypersensitivity has been suggested
by some authors,10 which might explain the large variability in the
onset time of corneal edema after taking amantadine. Corneal
edema of our cases improved within 4e6 weeks after cessation of
amantadine, which is consistent with previous reports.
In our cases, the ﬁnal corneal endothelial cell density decreased
signiﬁcantly despite recovery of corneal edema. Although the
baseline specular endothelial count data were unavailable due to
severe corneal edema, the ﬁnal endothelial cell density was obvi-
ously lower than that of an age-comparable population. Because
amantadine-related corneal edemawas found to be associatedwith
endothelial dysfunction and cell loss, corneal edema may be irre-
versible if the endothelial loss is signiﬁcant. Jeng et al10 reported a
case with bilateral corneal edema after taking amantadine. Pene-
trating keratoplastywas performed in one eye due to severe corneal
edema. Because amantadinewasnot ceased, the endothelial cell loss
maintained progression in both eyes, resulting in graft edema. After
cessation of amantadine, the graft edema subsided, and penetrating
keratoplasty was performed in the fellow eye to treat irreversible
corneal edema. Due to the possibility of irreversible corneal edema
after amantadine use, care must be taken when the patients are at
high riskwith factors such as old age, lowcorneal endothelial count,
corneal dystrophy, or grafted cornea.
All our cases presented with bilateral progressive painless visual
deterioration due to corneal stromal edema with Descemet’s folds
after an uneventful period of amantadine therapy. Anterior cham-
bers were all silent, without keratic precipitates or cells. Although
ocular side effects of amantadine includes superﬁcial punctate
C.C. Lin et al. / Taiwan Journal of Ophthalmology 4 (2014) 137e140140keratitis and epithelial edema,5e7 to our knowledge, stromal edema
are the most often reported manifestation of amantadine-related
keratopathy. Hence, in patients with bilateral progressive painless
corneal stromal edema without any clue to the disease entity,
careful medication review is an easy but crucial step prior to
invasive diagnostic procedures.
In elderly patients with Parkinson’s disease, depression, or other
physical illness, visual deterioration is easily overlooked due to
poor verbal expression. It should be kept in mind that amantadine
can cause corneal edema, and regular ophthalmological follow-up
is important in these patients.
In conclusion, amantadine can cause corneal edema after weeks,
months, or even years of its administration. Patients most often
present with bilateral corneal stromal edema without anterior
chamber reaction. Corneal edema usually subsides after cessation
of the drug, with irreversible corneal endothelial cell loss. It should
be used carefully in patients with a low corneal endothelial count.
Besides, ophthalmic consultation is suggested prior to and during
amantadine therapy. Careful medication review is crucial in pa-
tients with an unknown etiology of corneal edema.References
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